Friday Alert – AMBS

Recommended Stock Newsletters
#1. PennyStockWarfare
#2. Nova Stocks
#3. Penny Stock Finder

Investorgoodies Newsletter


Dear Investors,



Congratulation to Traders who got in on EDWY this morning making gains of 25%!  We have a cheap bio medical company with good prospects we think you might like.  If you missed our prior winner, don`t miss out on this one before it`s too late.    


We want to alert: AMBS

What does Amarantus BioScience Holdings, Inc.. (AMBS) do

Amarantus BioScience Holdings, Inc.  is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson`s disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF“) and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and TBI.

What is Amarantus BioScience Holdings, Inc. (AMBS) current research  

The Company’s lead therapeutic program Mesencephalic-Astrocyte-derived Neurotrophic Factor, or  MANF is a targeted therapeutic to address the underlying Programmed Cell Death (Apoptosis) associated with a wide range of devastating human disorders. The Company`s lead diagnostic program, NuroPro®, is aimed at developing diagnostic blood tests that are capable of early identification of apoptosis-related medical conditions while tracking their progression over time. Both programs will initially target Parkinson`s disease.

Amarantus’ Management Team and Board of Advisors have designed a business strategy to formulate and advance pre-clinical and clinical programs for the Company`s product candidates through successive de-risking milestones in order to maximize their commercial potential. The Company is also focused on making the assets attractive partnering targets for product development focused biotechnology, pharmaceutical, medical device and diagnostic companies.

What is Amarantus BioScience Holdings, Inc. (AMBS) recent news Recent News InvestorGoodies, Suite #302, New York, New York 10005, United States

This entry was posted in Stock Newsletters and tagged , , . Bookmark the permalink.

Comments are closed.